New donanemab dosing cuts ARIA-E risk, speeds MRI monitoring, and shows durable 3-year benefits with lasting biomarker gains in early Alzheimer’s.
John Sims, MD
Advertisement
Articles by John Sims, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
Psychiatry on Trial: Are Psychiatrists Responsible for Their Patients’ Criminal Behavior?
2
Diagnosing and Treating Alzheimer Disease: August's Key Developments
3
Bringing Wearable Device Data Into Psychiatric Care
4